The BRPTO has just published the final version of its newest examination guidelines for biotechnology-related patent applications, after the public consultation carried out between February and April 2019, and the analysis of a specialized committee.

The updated guidelines better define modifications related to the sufficiency of disclosure of biological sequence listings, such as the Markush formula of amino acid sequences, as well as the patentability requirements of degenerated nucleotide sequences, polyclonal antibodies, antibodies exposed to antigens, fully human monoclonal antibodies and antibodies fragments. The guidelines also elucidates the patentability of inventions related to human embryonic stem cells.

For more information (in Portuguese), please click here.

 

---